Drugs / Narlaprevir
Narlaprevir
Trials 7
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT03537404 | Apr → Jun 2017 | — | R-Pharm | Completed | No outcome recorded |
| Phase 1 | NCT03832426 | Nov 2013 → Oct 2014 | — | R-Pharm | Completed | No outcome recorded |
| Phase 1 | NCT01081158 | Jul 2007 → Aug 2008 | chronic hepatitis C virus infection | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT04246723 | May 2019 → Apr 2020 | chronic hepatitis C virus infection | R-Pharm | Completed | No outcome recorded |
| Phase 2 | NCT03485846 | Nov 2017 → Aug 2018 | chronic hepatitis C virus infection | R-Pharm | Completed | No outcome recorded |
| Phase 2 | NCT00797745 | Nov 2008 → Jul 2009 | chronic hepatitis C virus infection | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT03833362 | May 2014 → Mar 2016 | chronic hepatitis C virus infection | R-Pharm | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2/3 | NCT00689390 Background | Feb 2007 → Oct 2014 | chronic hepatitis C virus infection | Merck Sharp & Dohme LLC | Terminated | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 10 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Narlaprevir | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03485846 ↗ |
| Known as | NVR | “In this study we sought to evaluate narlaprevir (NVR) pharmacokinetics (PK) after a single dose with or without ritonavir (RTV) in cirrhotic versus healthy subjects.” PMID 27645244 ↗ Nov 2016 |
| Known as | SCH 900518 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00797745 ↗ |
| Action | Inhibit | “SCH 900518 is a potent oral inhibitor of HCV NS3 protease” NCT00797745 ↗ |
| Modality | Small molecule | — CHEMBL1255891 ↗ |
| Route | Oral | “SCH 900518 100 mg tablets taken as 200 mg PO QD, 100 mg PO BID, 400 mg PO QD, or 600 mg PO QD for 12 weeks.” NCT00797745 ↗ |